Effect of Hemodialysis on Pharmacokinetics of Ezogabine/Retigabine and its N-Acetyl Metabolite in Patients with End Stage Renal Disease

Publisher： Bentham Science Publishers

E-ISSN： 2212-3938|9|4|319-325

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.9, Iss.4, 2014-11, pp. : 319-325

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease

By Thompson-Culkin K   Zussman B   Miller AK   Freed MI  

The Journal of International Medical Research, Vol. 30, Iss. 4, 2002-07 ,pp. : 391-399

Field House Publishing

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Retigabine/Ezogabine

By  

Current Clinical Pharmacology, Vol. 8, Iss. 4, 2013-11 ,pp. : 319-331

Bentham Science Publishers

Access to resources Recommend Favorite

The pharmacokinetics (PK) of aprepitant are not affected in patients with end-stage renal disease (ESRD) or severe renal impairment

By  

Inpharma, Vol. 1, Iss. 1494, 2005-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

An unusual case of an irretrievable hemodialysis catheter in a patient with end stage renal disease

By  

Hemodialysis International, Vol. 22, Iss. 1, 2018-01 ,pp. : E1-E5

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics of Metrifonate and its Metabolite Dichlorvos in Healthy Volunteers and in Patients with Renal Impairment

By Heinig R.  

Clinical Drug Investigation, Vol. 18, Iss. 1, 1999-07 ,pp. : 35-46

Adis International

Access to resources Recommend Favorite